• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by I-MAB

    6/13/22 10:44:54 AM ET
    $IMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMAB alert in real time by email
    SC 13G 1 infiniimab13gjune2022.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.   )*



    I-MAB
    (Name of Issuer)
     
    Sponsored ADS
    (Title of Class of Securities)
     
    44975P 103
    (CUSIP Number)
     
    May 31, 2022
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☑ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     Infini Master Fund
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Cayman Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    5,004,206
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    5,004,206
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     5,004,206
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     6.06%(1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO, IA
     
     
     
     
     
    (1) Based on 189,855,096 ordinary shares of the Issuer issued and outstanding (excluding 877,631 ordinary shares issued to the Issuer's depositary bank for bulk issuance of American Depositary Shares ("ADSs") reserved for future issuances upon the exercising or vesting or awards granted under the Issuer's share incentive plans) as of February 28, 2022, as disclosed in the Issuer's prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(3) on March 31, 2022.  Each ten (10) ADSs represent twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market under the symbol "IMAB."


    Item 1(a). Name of Issuer:

     I-MAB (the "Issuer")
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

    Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District
    Shanghai, 201210
    People's Republic of China

    Item 2(a). Name of Persons Filing:

    This Schedule 13G is being jointly filed by Infini Capital Management Limited (the "Manager"), a private company limited by shares incorporated in Hong Kong and Infini Master Fund (the "Master Fund"), an exempted company incorporated in the Cayman Islands with limited liability with respect to the ownership of American Depositary Shares ("ADS") by the Master Fund.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     The address of the principal business office of the Master Fund is:

     c/o Walkers Corporate Limited
     Cayman Corporate Centre
     27 Hospital Road
     George Town, Grand Cayman
     KY1-9008
     Cayman Islands

     The address of the principal business office of the Manager is:

     Suites 1307-1308, 13/F, Two Exchange Square
     8 Connaught Place, Central
     Hong Kong



    Item 2(c). Citizenship:

     Master Fund:  Cayman Islands

     Manager:  Hong Kong

    Item 2(d). Title of Class of Securities:

    Sponsored ADS
     
    Item 2(e). CUSIP Number:

     44975P 103


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):

    Not applicable.

    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securiteis of the Issuer identified in Item 1.

      A.  Infini Master Fund
     
     
      
     


    (a) Amount beneficially owned: 5,004,206


    (b) Percent of class: 6.06%*


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 5,004,206

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 5,004,206
     

       B.  Infini Capital Management Limited
     
     
      
     


    (a) Amount beneficially owned: 5,004,206


    (b) Percent of class: 6.06%*


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 5,004,206

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 5,004,206
     

    *The beneficial ownership percentage reported herein is based on 189,855,096 ordinary shares of the Issuer issued and outstanding (excluding 877,631 ordinary shares issued to the Issuer's depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under the Issuer's share incentive plans) as of February 28, 2022, as disclosed in the Issuer's prospectus supplement filed with the Securities and Exchange Commission pursuant to Rule 424(b)(3) on March 31, 2022.  Each ten (10) ADSs representing twenty three (23) ordinary shares, which are quoted on the Nasdaq Global Market Fund under the symbol "IMAB."



    Item 5. Ownership of Five Percent or Less of a Class.

    Not Applicable

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     Not Applicable

    Item 8. Identification and Classification of Members of the Group.

     See Exhibit 1

    Item 9. Notice of Dissolution of Group.

     Not Applicable
     
    Item 10.
    Certifications.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
     


    SIGNATURE

    The undersigned certifies, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct.

    RULE 13-d-1(k)(1) AGREEMENT

    The undersigned persons agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the securities of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.


     
      Date:  June 13, 2022
       
     
    INFINI MASTER FUND
     
     
    By:
    /s/ Chin To Tony
       
    Name: Chin To Tony
       
    Title:    Director
     
     
     
    INFINI CAPITAL MANAGEMENT LIMITED
     
     
    By:
     /s/ Chin To Tony
       
    Name:  Chin To Tony
       
    Title:    Director


    Attachment A

    1. Items 4(a) and (b) of Schedule 13G

     As of  June 7, 2022, the Master Fund was the legal owner of 5,004,206 ADSs.  Based on there being 189,855,096 ordinary shares outstanding (excluding 877,631 ordinary shares issued to the Issuer's depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under the Issuer's share incentive plans) as of February 28, 2022, with each ten (10) ADSs representing twenty three (23) ordinary shares, the Master Fund's holding represents approximately 6.06% of the oustanding ADSs.

    The Manager serves as investment manager to the Master Fund and has discretionary and voting power over the shares held by the Master Fund. Accordingly, the Manager may be deemed to be the beneficial owner of 5,004,206 ADSs which are held by the Master Fund.

    The Manager disclaims beneficial ownership of the ADSs of the Issuer held by the Master Fund, except to the extent of any pecuniary interest therefrom, and this report shall not be deemed to be an admission that it is the beneficial owner of such securities.

    2. Item 4(c) of Schedule 13G

    As of June 7, 2022, each of the Manager and the Master Fund may be deemed to have the power to vote or to direct the voting of and to dispose or to direct the disposition of the 5,004,206 ADSs held by the Master Fund. 

    The Manager disclaims beneficial ownership of the shares of ADSs of the Issuer held by the Master Fund, except to the extent of any pecuniary interest therefrom, and this report shall not be deemed to be an admission that it is the beneficial owner of such securities.




    Exhibit 1
    AGREEMENT

    The undersigned hereby agree as follows:

    (i)  Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

    (ii)  Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.


     
      Date:  June 13, 2022
       
     
    INFINI MASTER FUND
     
     
    By:
    /s/ Chin To Tony
       
    Name:  Chin To Tony
       
    Title:    Director
     
     
     
    INFINI CAPITAL MANAGEMENT LIMITED
     
     
    By:
    /s/ Chin To Tony 
       
    Name:  Chin To Tony
       
    Title:    Director
     
    Get the next $IMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMAB

    DatePrice TargetRatingAnalyst
    12/9/2021$96.00Buy
    Siebert Williams Shank
    11/1/2021$83.00 → $85.00Buy
    Needham
    9/1/2021$75.00 → $95.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program

      Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritizationThe Company has completed enrollment of a dose escalation study of givastomig in combination with nivolumab plus chemotherapy, and data is expected in the early second half of 2025; a 40-patient dose expansion study is now underway with data expected in early 2026Cash balance of $184.4 million (as of September 30, 2024), expected to support operations into 2027, complemented by a strengthened U.S.-based leadership team and streamlined operating modelROCKVILLE, MD, Jan. 6, 2025 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based,

      1/6/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Third Quarter 2024 Results

      Givastomig data presented at ESMO 2024 and SITC 2024 highlights encouraging monotherapy dataOn track to dose first patient in randomized Phase 2 study of uliledlimab in first-line mNSCLC in 1H 2025Appointed Dr. Sean Fu as permanent CEO effective November 1, 2024Estimated cash runway into 2027, based on $184.4 million in cash and cash equivalents, and short-term investments as of September 30, 2024ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced financial results for the three and nine months ended

      11/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Financials

    Live finance-specific insights

    See more
    • I-Mab to Release Q3 2024 Financial Results on November 14, 2024

      ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. The Company will not host a conference call to discuss its third quarter 2024 financial results. The Company intends to host an investor update call in conjunction with its 2024 full-year fin

      10/31/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates

      Completed divestiture of China operationsUliledlimab IND clearance paves the way for U.S. combination studies in first-line mNSCLC (CD73 antibody)Clinical collaboration and supply agreement with Bristol Myers Squibb strengthens givastomig first-line gastric cancer combination studies (CLDN18.2 X 4-1BB bispecific)Ragistomig presentation at ASCO 2024 highlights encouraging early data (PD-L1 X 4-1BB bispecific)Well-positioned for pipeline advancement with $207.5 million in cash and cash equivalents, and short-term investments as of June 30, 2024, and cash runway expected into 2027I-Mab will hold a conference call and webcast today, August 28th, at 8:00 AM ETROCKVILLE, Md., Aug. 28, 2024 /PRNews

      8/28/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Release 1H 2024 Financial Results on August 28, 2024

      Conference call to discuss financial results and recent business highlights to take place on Wednesday, August 28, 2024, at 8:00 AM ET ROCKVILLE, Md., Aug. 14, 2024 /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to host a conference call and webcast on Wednesday, August 28, 2024, 8:00 AM ET to discuss financial results, pipeline progress and recent business highlights for the half year ended June 30, 2024.

      8/14/24 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/13/24 11:26:50 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by I-MAB (Amendment)

      SC 13G/A - I-Mab (0001778016) (Subject)

      2/9/24 4:01:20 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by I-MAB

      SC 13D - I-Mab (0001778016) (Subject)

      12/1/23 2:41:06 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    SEC Filings

    See more
    • SEC Form F-3 filed by I-MAB

      F-3 - I-Mab (0001778016) (Filer)

      5/2/25 5:01:56 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/30/25 7:14:42 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by I-MAB

      6-K - I-Mab (0001778016) (Filer)

      4/4/25 4:59:51 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Siebert Williams Shank initiated coverage on I-Mab with a new price target

      Siebert Williams Shank initiated coverage of I-Mab with a rating of Buy and set a new price target of $96.00

      12/9/21 8:33:47 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on I-MAB with a new price target

      Needham reiterated coverage of I-MAB with a rating of Buy and set a new price target of $85.00 from $83.00 previously

      11/1/21 4:39:06 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on I-MAB with a new price target

      HC Wainwright & Co. reiterated coverage of I-MAB with a rating of Buy and set a new price target of $95.00 from $75.00 previously

      9/1/21 6:14:32 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025

      ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be held July 2-5 in Barcelona, Spain. "We are very pleased to receive confirmation that new clinical data for givastomig has been accepted as an oral presentation at the upcoming ESMO Gastrointestinal Cancers Congress 2025. As more information becomes available fr

      4/30/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

      Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., April 03, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology

      4/3/25 4:01:00 PM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

      ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab's management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ETWebcast Link:Register here   About I-Mab I-Mab (NASDAQ:IMAB) is a US-based, global biotech company, focused on the developm

      3/26/25 7:00:00 AM ET
      $IMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care